Brief: Marker Therapeutics Reports Pre-Clinical Data Of T Cell Product Candidate In Lymphoma Cells
31/05/2023 11:46
May 31 (Reuters) - Marker Therapeutics Inc MRKR.O :
* MARKER THERAPEUTICS REPORTS PRE-CLINICAL DATA OF ITS
MT-601
MULTITAA-SPECIFIC T CELL PRODUCT CANDIDATE IN LYMPHOMA CELLS
Source text for Eikon: ID:nGNX5CrmV4
Further company coverage: MRKR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79